Drug intelligence / Profile preview

HP-003

Development stage: Preclinical
Lead developer: Shanghai Chaoyang Pharmaceutical
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

HP-003 is a molecular glue degrader being developed by Shanghai Helioson Pharmaceutical for the treatment of autoimmune diseases. It is part of the company's protein homeostasis platform, which focuses on using molecular glues and PROTACs to target previously undruggable proteins. As of early 2024, HP-003 is in the discovery or early preclinical stage of development, and its specific molecular target has not been disclosed.

Targets

VAV1 (Guanine nucleotide exchange factor VAV1)

Beyond the preview

Go deeper on HP-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP-003.

Explore the full profile